Clinical trials: Diffuse Large-Cell Lymphoma
Diffuse Large B-cell Lymphoma
TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
The purpose of this study is to assess the efficacy of TAK-659 measured by independent radiologic review committee (IRC)-assessed overall response rate (ORR) in participants with relapsed or refractory DLBCL.
- Trial name
- NCT03123393
- Testing
- TAK-659
- Where
- 41 sites in United States, Canada and 4 more
- Volunteers
- 49 people
- Sponsor
- Calithera Biosciences, Inc
Primary Mediastinal B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma (MCL)
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
To study the safety and efficacy of cord blood-derived CD19 CAR-NK cells sequential with 7x19 CAR-T in relapse / refractory B cell lymphoma
- Conditions
- Primary Mediastinal B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma( DLBCL)
- Trial name
- CD19-CARNK/T (NCT06464861)
- Testing
- CD19-CAR-NK/T
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cervical Cancer, Chronic Myeloproliferative Disorders
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
RATIONALE: The use of dalteparin may be able to prevent complications caused by the use of a catheter to supply chemotherapy to cancer patients. It is not yet known if dalteparin is effective in reducing these complications.
- Conditions
- Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00006083
- Testing
- Fragmin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Lymphoma, Large B-cell, Diffuse
Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)
This study will validate the impact of comprehensive geriatric assessments using activity of daily living (ADL), instrumental activity of daily living (IADL), and Charlson's comorbidity index (CCI) on survival and toxicities in…
- Trial name
- NCT03211702
- Where
- 2 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Chonbuk National University Hospital
Diffuse Large B-cell Lymphoma
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
A multi-center, open-label, phase Ib study to evaluate the safety and efficacy of the administration of tisagenlecleucel in combination with pembrolizumab in patients with r/r DLBCL who have received 2 or more lines of systemic…
- Trial name
- PORTIA (NCT03630159)
- Testing
- Tisagenlecleucel, Pembrolizumab
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies
The purpose of this study is to evaluate the safety, tolerability, dose-limiting toxicities (any harmful effect of a drug) (DLT), maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and preliminary clinical activity of…
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell
- Trial name
- NCT02454270
- Testing
- Part 1 (Dose Escalation): Duvortuxizumab, Part 2 (Dose Expansion): Duvortuxizumab
- Where
- 20 sites in United States, Belgium and 3 more
- Volunteers
- 59 people
- Sponsor
- Janssen Research & Development, LLC
Burkitt's Lymphoma, Burkitt's Leukemia
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults
The study evaluates the efficacy and tolerability of alternating short cycles of high-dose and conventional chemotherapy in combination with rituximab in CD20 positive patients, followed by local radiation therapy in the case of…
- Conditions
- Burkitt's Lymphoma, Burkitt's Leukemia, Mediastinal Neoplasms, Lymphoblastic Lymphoma
- Trial name
- NCT00199082
- Testing
- Adriamycin, Cyclophosphamide, Cytarabine
- Where
- Germany
- Volunteers
- 650 people
- Sponsor
- Nicola Goekbuget
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
This study is designed to determine the recommended phase 2 dose (RP2D), and the safety, and efficacy of durvalumab as monotherapy and when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and…
- Trial name
- FUSION NHL 001 (NCT02733042)
- Testing
- Durvalumab, Lenalidomide, Rituximab
- Where
- 66 sites in United States, France and 5 more
- Volunteers
- 106 people
- Sponsor
- Celgene
Leukemia, Lymphoma
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00014560
- Testing
- bispecific antibody 4G7xH22, sargramostim
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
This study will evaluate the efficacy of the combination entospletinib and idelalisib in participants with relapsed or refractory hematologic malignancies.
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin's Lymphoma
- Trial name
- NCT01796470
- Testing
- Entospletinib, Idelalisib
- Where
- 13 sites in United States
- Volunteers
- 66 people
- Sponsor
- Gilead Sciences
Primary Gastric Diffuse-Large B-Cell Lymphoma
Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The optimal treatment of primary gastric diffuse large B-cell lymphoma (PG-DLBCL) has not yet been defined. In most circumstances, a stomach-conserving approach is favored, but the role of radiotherapy is still a matter of…
- Trial name
- NCT00204659
- Testing
- Rituximab + CHOP chemotherapy
- Where
- 5 sites in Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Tuebingen
Lymphoma
Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb
The Phase II study proposed here assesses the hypothesis that replacing doxorubicin by Myocet® in the R-CHOP regimen would yield comparable antitumour efficacy with a lower cardiotoxicity for first-line treatment in elderly…
- Trial name
- NCT02012088
- Testing
- RCOMP, RCHOP
- Where
- 14 sites in Spain
- Volunteers
- 91 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma
The purpose of this first in human study is to assess safety, tolerability, PK and preliminary clinical activity and to estimate the MTD(s)/RDE(s) of MIK665 (also referred as S64315) as single agent administered intravenously…
- Trial name
- NCT02992483
- Testing
- MIK665
- Where
- 8 sites in United States, Australia and 5 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
NSCLC, SCLC
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research.
- Conditions
- NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT06534762
- Testing
- Mirabegron
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Zhejiang Provincial People's Hospital
Breast Cancer, Chronic Myeloproliferative Disorders
Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients
RATIONALE: Understanding the emotional needs of spouses or others who are living with and caring for patients who have undergone stem cell transplantation may help improve the quality of life of both the caregivers and the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00082654
- Testing
- psychosocial assessment and care
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, Waldenström Macroglobulinemia (WM)
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
- Conditions
- Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma, PMBCL
- Trial name
- NCT07249905
- Testing
- MDX2003
- Where
- 6 sites in Australia, Israel
- Volunteers
- 180 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Lymphoma, Large B-Cell, Diffuse
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
This Phase Ib, open-label, multicenter study evaluates the safety, efficacy, and pharmacokinetics of venetoclax in combination with Pola + R-CHP in previously untreated participants with BCL-2 IHC-positive DLBCL.
- Trial name
- NCT04790903
- Testing
- Venetoclax, Polatuzumab Vedotin, Rituximab
- Where
- 20 sites in United States, France and 2 more
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Extranodal Lymphoma
A Retrospective Study on Extranodal DLBCL
The aim of this study is to prospectively collect clinical information of patients with extranodal DLBCL, assess the effectiveness of treatment for extranodal DLBCL in the real world, and explore the optimal treatment strategies…
- Conditions
- Lymphoma, Extranodal Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06549361
- Testing
- No interventions need to be specified for this study
- Where
- China
- Volunteers
- 5,023 people
- Sponsor
- Ruijin Hospital
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
This phase I trial studies the side effects and best dose of olaparib when given together with high-dose chemotherapy in treating patients with lymphomas that have come back or does not treatment and are undergoing stem cell…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma
- Trial name
- NCT03259503
- Testing
- Busulfan, Gemcitabine, Melphalan
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Diffuse Large B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA)
The goal of this study is to identify biomarkers that will predict outcome to standard and targeted therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- MIMOSA (NCT05746858)
- Testing
- no intervention (observational study)
- Where
- 3 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.